膜联蛋白A5和CD147在喉癌组织中的表达

目的分别观察膜联蛋白A5（ANX A5）和细胞外基质金属蛋白酶诱导因子（CDl47）在癌旁正常组织和喉癌组织中的表达情况，分析喉癌组织中ANX A5和CD147表达的相关性。 方法收集2012年1月至2018年2月经川北医学院附属医院耳鼻咽喉-头颈外科手术切除，并经病理学确诊的喉癌组织标本51例和癌旁组织标本35例，运用免疫组化SP法分别检测喉癌组织标本与癌旁组织标本中ANX A5和CD147的表达情况。采用四格表χ²检验分析不同病理、临床特点喉癌患者中ANX A5、CD147的表达情况，采用Spearman等级相关分析分析喉癌组织中ANX A5和CD147表达的相关性。 结果ANX A5和CD147在喉癌组织中的表达水平均高于癌旁组织中的表达水平（χ²=6.939，P=0.008；χ²=14.722，P<0.001）。与TNM分期Ⅰ~Ⅱ期患者、喉癌组织病理学分级为低-未分化患者、无颈淋巴结转移患者相比，TNM分期Ⅲ~Ⅳ期患者、喉癌组织病理学分级为高-中分化患者、存在颈淋巴结转移患者中ANX A5的表达水平更高，差异均有统计学意义（χ²=5.298，P=0.021；χ²=3.869，P=0.049；χ²=8.419，P=0.004）；≥60岁和<60岁患者以及不同性别患者中ANX A5的表达水平差异无统计学意义（χ²=0.003，P=0.957；χ²=0.082，P=0.775）。与TNM分期Ⅰ~Ⅱ期、无颈淋巴结转移患者相比，TNM分期Ⅲ~Ⅳ期、存在颈淋巴结转移的喉癌患者中CD147具有更高的表达水平，差异具有统计学意义（χ²=14.009，P<0.001；χ²=11.004，P=0.001）；≥60岁和<60岁患者、不同性别患者以及不同病理学分级患者中CD147的表达水平差异无统计学意义（χ²=1.546，P=0.214；χ²=1.373，P=0.241；χ²=0.002，P=0.964）。Spearman等级相关分析显示喉癌组织中ANX A5与CD147的表达呈正相关（r=0.918，P<0.001）。 结论ANX A5和CD147在喉癌组织中的表达水平均高于癌旁组织，且在具有不同病理、临床特点的喉癌患者中存在表达水平的差异，提示ANX A5与CD147可能参与喉癌的发生、发展。

Expression of ANX A5 and CD147 in human laryngeal carcinoma

ObjectiveTo observe the expression of annexin A5 (ANX A5) and extracellular matrix metalloproteinase inducible factor (CD147) in laryngeal carcinoma and tumor adjacent normal tissues, and to analyze the correlation between the expression of ANX A5 and CD147 in laryngeal carcinoma. MethodsImmunohistochemical SP method was used to detect the expression of ANX A5 and CD147 in 51 laryngeal carcinoma tissues and 35 tumor adjacent tissues. The expression of ANX A5 and CD147 in laryngeal cancer patients with different pathological and clinical characteristics was analyzed by the quadruple table χ² test, and the correlation between the expression of ANX A5 and CD147 in laryngeal cancer tissues was analyzed by Spearman correlation analysis. ResultsThe expression levels of ANX A5 and CD147 in laryngeal carcinoma tissues were higher than those in tumor adjacent tissues (χ²=6.939, P=0.008; χ²=14.722, P<0.001). Compared with patients with TNM stageⅠ-Ⅱ disease, patients with low-undifferentiated laryngeal carcinoma, and patients without cervical lymph node metastasis, the expression level of ANX A5 was significantly higher in patients with TNM stage Ⅲ-Ⅳ disease, patients with highly-to-moderately differentiated laryngeal carcinoma, and patients without cervical lymph node metastasis, respectively (χ²=5.298, P=0.021; χ²=3.869, P=0.049; χ²=8.419, P=0.004); there was no significant difference in the expression level of ANX A5 between patients aged≥ 60 and<60 years and between patients of different sexes (χ²=0.003, P=0.957; χ²=0.082, P=0.775). Compared with patients with TNM stageⅠ-Ⅱ disease and patients without cervical lymph node metastasis, the expression of CD147 was significantly higher in patients with stage Ⅲ-Ⅳ disease and patients with cervical lymph node metastasis, respectively (χ²=14.009, P<0.001; χ²=11.004, P=0.001). There was no significant difference in the expression of CD147 between patients over 60 years old and those under 60 years old, between patients of different genders, and between patients with different pathological grades (χ²=1.546, P=0.214; χ²=1.373, P=0.241; χ²=0.002, P=0.964). Spearman rank correlation analysis showed that ANX A5 expression was positively correlated with CD147 expression in laryngeal carcinoma (χ²=0.918, P<0.001). ConclusionThe expression levels of ANX A5 and CD147 in laryngeal carcinoma tissues are higher than those in adjacent tissues, and there are differences in the expression levels of ANX A5 and CD147 among laryngeal carcinoma patients with different pathological and clinical characteristics, suggesting that ANX A5 and CD147 may participate in the occurrence and development of laryngeal carcinoma.